ClinicalTrials.gg
RecruitingNCT06855784TREMHOUpdated Jan 27, 2026

Time-Restricted Eating in Menopause and HOrmone-sensitive Breast Cancers (TREMHO)

An interventional study of Time-Restricted Eating 16h/8h and Active Control in Menopause and Obesity and Overweight, sponsored by University Hospital, Geneva. Recruiting at 1 site in Switzerland. Open to female participants aged 45 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by University Hospital, Geneva · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
45 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Obesity with a site in Switzerland — 22 open to participants now, 30 under way, 5 of them phase 3. Obesity · Switzerland.

Planned enrollment
32nd of 90
84 · median 64
Started
2025
with 8 others
No phase
64 of 127
9 open now
Primary completion
2027-03
later than 10 of 29 live
Registered
114th of 127
by date
Lead sponsor
8 of 127
University Hospital, Geneva

Among the 127 studies in Obesity with a site in Switzerland, this one is the 32nd largest by planned enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2025, is one of 64 with no phase, reaches primary completion later than 10 of the 29 other live ones, and was the 114th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

22 of the 127 studies in Obesity with a site in Switzerland are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 45 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Obesity with a site in Switzerland, or all of them as a file.
02

Study summary

This study is aimed at women currently going through menopause, either as part of the natural process (physiological menopause), or following hormonal treatment for breast cancer. There are several ways of slowing the weight gain frequently encountered in this situation, reducing the intensity of menopause-related symptoms and improving quality of life in this context.

In this trial, the investigators examine the efficacy and possible adverse effects of intermittent fasting compared with a control intervention. Participation lasts 14 weeks, with an optional 12-month follow-up. Study participants are randomly assigned to either the intervention group or the control group. In the intervention group, study participants fast for 16 hours per day and eat over a period of 8 hours (intermittent fasting often called time-restricted eating [TRE] 16h/8h). In the control group, the usual eating pattern is continued for 12 weeks.

The main objective of the study is to evaluate the efficacy of TRE in terms of weight and fat loss, improvement in metabolic profile, menopausal symptoms and bone health. In addition, the study team closely monitors any adverse effects.

03

Conditions studied

  • Menopause
  • Obesity and Overweight
04

Who can participate

Ages eligible
45 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with confirmed physiological menopause without current anti-cancer treatment (group A), or women with menopausal symptoms in the context of aromatase inhibitors used as therapy for hormone-sensitive non- breast cancers regardless of physiological menopause before the cancer diagnosis (group B)
  • Age 40-65 years
  • 25-40 kg/m2
  • Stable weight (± 2 kg) over the previous month
  • Eating window ≥ 12 hours (self-reported and measured during the run-in phase)
  • Able to give and follow the study procedures for the entire duration
  • Confident use of a smartphone and able to take regular pictures of food/drinks

Exclusion criteria

Exclusion Criteria:

  • On a hypocaloric restrictive diet, intermittent fasting or in a weight management program over the previous month
  • Previous bariatric surgery or planned during the study
  • Active eating disorder(s) or major mental illness at inclusion
  • Psychoactive treatment with recent or planned changes of drug compound or dosage
  • Treatments affecting body weight (e.g. , GLP-1 receptor analogues)
  • Diabetes with hypoglycemic drug(s) will be excluded, however those with prediabetes (as defined by the American Diabetes Association) or diabetes with no risk of hypoglycemia (i.e. treated with non-hypoglycemic drugs or without medication) will be included
  • Active metabolic bone diseases (e.g. Paget disease, osteomalacia), however women with osteoporosis will be included
  • Shift work comprising night shifts (working between 11pm and 6am) over the previous 2 weeks or planned during the study
  • Travel/trip to a different time zone (≥ 2-hour time difference) over the previous 2 weeks or planned during the study
  • Enrolled in another interventional clinical trial (medication, surgery, medical device) over the previous 2 weeks or planned during the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Time-Restricted Eating

    Behavioral: Time-Restricted Eating 16h/8h

  • Active comparator
    Active Control

    Behavioral: Active Control

Interventions

  • BehavioralTime-Restricted Eating 16h/8h

    Participants will be advised to eat only during a self-selected window of 8 hours over the 24-hour cycle, with a 1-hour allowance according to their daily routine.

    Also known as: TRE 16h/8h

  • BehavioralActive Control

    Participants will be advised to eat 2 to 3 meals every day according to their eating habits and social activities

06

What researchers measure

Primary outcomes

  1. Changes in body weight

    Measured (in Kg) in light clothing using a calibrated medical-grade scale

    Time frame: From randomization visit to close-out visit (12 weeks)

  2. Changes in body fat mass

    Measured (in Kg) by dual-energy x-ray absorptiometry (DXA)

    Time frame: From randomization visit to close-out visit (12 weeks)

Secondary outcomes

  1. Changes in menopause / climacteric symptoms

    Assessed by questionnaire

    Time frame: From randomization visit to close-out visit (12 weeks)

  2. Changes in bone mineral density

    Measured (in g/cm3) by dual-energy x-ray absorptiometry (DXA)

    Time frame: From randomization visit to close-out visit (12 weeks)

  3. Changes in bone turnover marker CTX

    C-telopeptide cross-linked type 1 collagen (CTX) measured (in ng/L) by clinical chemistry

    Time frame: From randomization visit to close-out visit (12 weeks)

  4. Changes in bone turnover marker P1NP

    Procollagen type 1 N-terminal propeptide (P1NP) measured (in μg/L) by clinical chemistry

    Time frame: From randomization visit to close-out visit (12 weeks)

  5. Changes in joint pain

    Joint pain assessed by questionnaire (0 = absent to 7 = Extremely bothered)

    Time frame: From randomization visit to close-out visit (12 weeks)

  6. Changes in body mass index (BMI)

    Expressed in percent of baseline value (body mass index = weight in Kg divided by the height in meters squared, unit Kg/m2)

    Time frame: From randomization visit to close-out visit (12 weeks)

  7. Changes in waist circumference

    Measured (in cm) with a measuring tape, following the WHO 2008 Expert Report

    Time frame: From randomization visit to close-out visit (12 weeks)

  8. Changes in hip circumference

    Measured (in cm) with a measuring tape, following the WHO 2008 Expert Report

    Time frame: From randomization visit to close-out visit (12 weeks)

  9. Changes in systolic and diastolic blood pressure

    Measured (in mmHg) with an arm cuff in the sitting position

    Time frame: From randomization visit to close-out visit (12 weeks)

  10. Changes in fasting plasma glucose

    Measured (in mmol/L) by clinical chemistry

    Time frame: From randomization visit to close-out visit (12 weeks)

  11. Changes in lipid profile

    Total cholesterol, LDL cholesterol, triglycerides and HDL cholesterol concentrations measured (in mmol/L) by clinical chemistry

    Time frame: From randomization visit to close-out visit (12 weeks)

  12. Changes in lean body mass

    Measured (in Kg) by dual-energy x-ray absorptiometry (DXA)

    Time frame: From randomization visit to close-out visit (12 weeks)

  13. Changes in body composition

    Fat mass and fat-free mass (in Kg) measured by bioelectrical impedance analysis (BIA)

    Time frame: From randomization visit to close-out visit (12 weeks)

  14. Changes in muscle function

    Measured (in Kg) by handgrip strength

    Time frame: From randomization visit to close-out visit (12 weeks)

  15. Changes in glucose excursion

    Measured by continuous glucose monitoring

    Time frame: From randomization visit to close-out visit (12 weeks)

  16. Changes in metabolomic profile

    Measured by high-throughput mass spectrometry metabolomics

    Time frame: From randomization visit to close-out visit (12 weeks)

  17. Changes in physical activity

    Measured by actigraphy (in activity counts, CamNTech proprietary algorithm) and by the International Physical Activity Questionnaire (IPAQ, aggregated in MET-minutes/week)

    Time frame: From randomization visit to close-out visit (12 weeks)

  18. Changes in sleep/wake cycles

    Measured by actigraphy assessed as time of sleep onset and wake-up in 24-hour cycle

    Time frame: From randomization visit to close-out visit (12 weeks)

  19. Changes in sleep duration

    Measured by actigraphy

    Time frame: From randomization visit to close-out visit (12 weeks)

  20. Changes in body temperature

    Measured by body temperature wearable device

    Time frame: From randomization visit to close-out visit (12 weeks)

  21. Changes in sleep quality

    Assessed by the Pittsburgh Sleep Quality Index \[PSQI, minimum score = 0 (better); maximum score = 21 (worse)\]

    Time frame: From randomization visit to close-out visit (12 weeks)

  22. Changes in eating duration

    Duration from the first to last caloric intake over 24-hour cycle

    Time frame: From randomization visit to close-out visit (12 weeks)

07

Study locations

1 of 1 sites recruiting
  • Geneva University Hospitals
    Geneva, Canton of Geneva 1211, Switzerland
    Recruiting
    • Tinh-Hai Collet, MD · Contacttinh-hai.collet@hug.ch · +41-22-372 91 92
    • Isabelle Streuli, MD · Sub investigator
    • Anita Wolfer, MD, PhD · Sub investigator
    • Alexandre Bodmer, MD · Sub investigator
    • Emmanuel Biver, MD, PhD · Sub investigator
    • Maria Papageorgiou, PhD · Sub investigator
    • Charna Dibner, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 22 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2025
First posted
Mar 4, 2025
StartActual
Apr 30, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06855784
Responsible party
Tinh-Hai Collet, MD (Assistant Professor, University Hospital, Geneva) — Principal investigator
First posted
Mar 4, 2025
Start date
Apr 30, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Jan 27, 2026

Study contacts

Tinh-Hai Collet, MD
Contact
tinh-hai.collet@hug.ch
+41-22-372 91 92
Céline Joris, BSc
Contact
celine.joris@hug.ch

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion